此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Dupilumab 降级治疗小儿特应性皮炎:一项试点试验

2026年11月2日 更新者:Johns Hopkins University

This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

研究概览

详细说明

Participants will be randomly assigned to one of three groups: discontinuation of dupilumab; reduction of dupilumab dose; or continuation of standard dupilumab dose. During the active study treatment period, participants will be asked to complete 5 study visits. At these visits, a physician will conduct a skin examination to assess atopic dermatitis (AD) severity and participants will complete questionnaires about their AD symptoms and severity. During the observational period, participants will be asked to complete questionnaires about their AD symptoms and medication use every twelve weeks, for a total of 3 follow-up contacts. The purpose of this study is to evaluate the feasibility and sustainability of reducing or discontinuing dupilumab in children with well-controlled AD.

研究类型

介入性

注册 (实际的)

1

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21210
        • Johns Hopkins Univerisity

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1年 至 17年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Aged 1 to <18 years old, either sex, any race or ethnicity
  • Provide signed informed consent by parent or legal guardian and informed assent if applicable
  • Has a physician confirmed diagnosis of atopic dermatitis
  • Has received dupilumab for at least 12 months for the treatment of atopic dermatitis
  • Has had well-controlled atopic dermatitis on dupilumab within last 6 months (defined as POEM<=7, EASI<=7, or IGA<=2)
  • Able to speak English
  • Able and willing to adhere to all study procedures

Exclusion Criteria:

  • Taking concurrent systemic medication for atopic dermatitis (e.g., methotrexate, cyclosporine, tralokinumab, abrocitinib, upadacitinib, systemic corticosteroids)
  • Using concurrent phototherapy for atopic dermatitis
  • Taking dupilumab for a clinical indication other than atopic dermatitis (such as asthma or eosinophilic esophagitis)
  • Poor control of atopic dermatitis
  • Poor control of asthma or eosinophilic esophagitis
  • Has used an investigational drug within 90 days or plan to use an investigational drug during the study period
  • Does not have health insurance or will lose health insurance during the study period

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Dupilumab - discontinuation

Participants will discontinue their dupilumab treatment for atopic dermatitis.

Drug injections are discontinued.

其他名称:
  • 双色素
实验性的:Dupilumab - dose reduction

Participants whose standard dupilumab dosing for atopic dermatitis is 200 mg or 300 mg every 2 weeks will decrease drug administration to every 4 weeks, and participants whose standard dupilumab dosing is 200 mg or 300 mg every 4 weeks will decrease administration to every 8 weeks.

The drug is given as a subcutaneous injection.

其他名称:
  • 双色素
实验性的:Dupilumab - standard dosing

Participants will continue to receive standard maintenance dupilumab dosing for atopic dermatitis according to FDA labeling, as indicated below.

Infants ≥6 months and Children <6 years:

5 to <15 kg: 200 mg every 4 weeks. 15 to <30 kg: 300 mg every 4 weeks

Children ≥6 years and Adolescents ≤17 years:

15 to <30 kg: 300 mg every 4 weeks 30 to <60 kg: 200 mg every other week

≥60 kg: 300 mg every other week

The drug is given as a subcutaneous injection.

其他名称:
  • 双色素

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants with Successful Dose Reduction of Dupilumab
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

Successful de-escalation is defined as maintaining a reduced dose (i.e., less frequent administration) of dupilumab after initial de-escalation on week 0. Patients who require re-escalating the dose of dupilumab to standard dosing or adding other systemic treatments for their AD will be regarded as treatment failure.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Percentage of Participants with Successful Discontinuation of Dupilumab
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

Successful discontinuation is defined as maintaining discontinuation of dupilumab after initial discontinuation on week 0. Patients who require resumption of dupilumab or beginning other systemic treatments for their AD will be regarded as treatment failure.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

次要结果测量

结果测量
措施说明
大体时间
Change in Investigator's Global Assessment (IGA) Scores
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

IGA is a global clinical assessment scale to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on the degree of erythema and papulation/infiltration. The IGA score ranges from 0 to 4. Higher scores indicate greater severity of AD.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Eczema Area and Severity Index (EASI) Scores
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The EASI score is used to evaluate severity of AD based on AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. The total EASI score ranges from 0 to 72. Higher scores indicate greater severity of AD.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient Oriented Eczema Measure (POEM) Scores
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The POEM is a 7-item questionnaire to assess disease symptoms in children and adults with AD. It is composed of 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) based on symptom frequency during the past week (0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The total POEM score ranges from 0 to 28. Higher scores indicate more severe disease and poor quality of life.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Itch questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Itch questionnaire measures the extent to which patients experience problems with itchiness over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Rarely; 3 = Sometimes; 4 = Often; and 5 = Almost Always). Higher scores reflect greater severity of experienced itch symptoms.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Problem questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Sleep Problem questionnaire measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Almost always; and 5 = Always). The sleep problems contain sleep disturbances (sleep quality, sleep onset, sleep continuity) and sleep-related impairment (perceptions of sleepiness during usual awake hours and reported impairments during the day associated with sleep problems or daytime sleepiness). Higher scores reflect greater severity of sleep problems.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Anxiety questionnaire measures the extent to which patients experience problems with anxiety over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Often; and 5 = Almost Always). The questionnaire includes fear (fearfulness, panic), anxious misery (worry, dread), hyperarousal (tension, nervousness, restlessness), social/separation anxiety (fear or distress when separating from caregivers), and somatic symptoms related to arousal (racing heart, dizziness). Higher scores reflect greater severity of experienced anxiety symptoms.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Depressive Symptoms questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Depressive Symptoms questionnaire measures the extent to which patients experience problems with depression over the past 7 days using a 5-point Likert scale (1 = Never; 2 = Almost never; 3 = Sometimes; 4 = Almost Always; and 5 = Always). The depressive symptoms include negative mood (sadness, guilt), views of self (self-criticism, worthlessness), and social cognition (loneliness, interpersonal alienation); decreased positive affect, anhedonia (loss of interest, inability to engage in play), and engagement. Higher scores reflect greater severity of experienced depressive symptoms.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Cognitive Function questionnaire measures the extent to which patients experience problems with cognitive function over the past 4 weeks using a 5-point Likert scale (1 = All of the time; 2 = Most of the time; 3 = Some of the time; 4 = A little of the time; and 5 = None of the time). The questionnaire includes difficulties in cognitive abilities (e.g., memory, attention, and decision making), and difficulties in the application of such abilities to everyday tasks (e.g., planning, organizing, calculating, remembering, and learning). Lower scores reflect greater impact on cognitive function.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Global Health questionnaire measures the extent to which patients experience problems with global health in general using a 5-point Likert scale (1 = Poor; 2 = Fair; 3 = Good; 4 = Fair; and 5 = Excellent). The questionnaire includes an overall evaluation of physical, mental health, and social health. Higher scores reflect a lower quality of global health.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity questionnaire score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The PROMIS Pain Intensity questionnaire measures the intensity of patients' pain due to their AD over the past 7 days using a 10 point scale, with 0 indicating "No Pain" and 10 indicating "the worst pain possible." Higher raw scores reflect greater severity of experienced pain due to AD.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Children's Dermatology Life Quality Index (CDLQI) score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

CDLQI is a 10-item questionnaire to assess the impact of skin problems on the quality of life of children between the ages of 4-16 years old over the last one week. Each question is evaluated on a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. Higher scores indicate worse child-reported quality of life. CDLQI scores indicate the degree of severity burden on the quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Change in Family Dermatology Life Quality Index (FDLQI) score
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

FDLQI is a 10-item questionnaire to assess the impact of skin problems on the quality of life of families over the last one month. Each question is evaluated on a 4-point scale: Not at all = 0, A Little = 1, Quite A Lot = 2, Very Much = 3. Higher scores indicate worse quality of life. FDLQI scores indicate the degree of severity burden on the quality of life: No effect = 0-1; Small effect = 2-6; Moderate effect = 7-12; Very large effect = 13-18; and Extremely large effect = 19-30.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Changes in Utilization of Topical Medications for Atopic Dermatitis
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

Participants will provide a self-report of their daily utilization of topical medications (medication name, dose and frequency) using a paper-form Daily Diary.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)
Adverse Events After Dupilumab Dose-reduction or Discontinuation
大体时间:From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

The number of participants who experience adverse events ≥ Grade 2 is based on the Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE is generally graded as follows: Grade 1 - mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not needed; Grade 2 - moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living; Grade 3 - severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limited self care activities of daily living; Grade 4 - life-threatening consequences; urgent intervention indicated; Grade 5 - death related to adverse event.

From Baseline through Week 16 (active protocol phase) and Week 17 through Week 52 (observational phase)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Joy Wan, MD MSCE、Johns Hopkins University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年4月1日

初级完成 (实际的)

2026年7月18日

研究完成 (实际的)

2026年7月18日

研究注册日期

首次提交

2023年10月30日

首先提交符合 QC 标准的

2023年10月30日

首次发布 (实际的)

2023年11月3日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅